Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
Abebe Muche Belete,1 Daniel Seifu,2 Menakath Menon,3 Wondwossen Amogne,4 Aster Shewa,5 Alemu Adela Tefera1 1Department of Biochemistry, Medical Faculty, Debre Berhan University, Debre Berhan, Ethiopia; 2Department of Biochemistry, Division of Biomedical Sciences, University of Global Health Equity,...
Guardado en:
Autores principales: | Muche Belete A, Seifu D, Menon M, Amogne W, Shewa A, Adela Tefera A |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9f4e7399e88841d18af284d46046ebd0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
por: Stephen I. Walimbwa, et al.
Publicado: (2021) -
Patient Reported Central Nervous System Adverse Events of Efavirenz-Based Antiretroviral Therapy in People Living with HIV in Northwest Ethiopia
por: Muche EA, et al.
Publicado: (2020) -
Dyslipidemia and Associated Factors Among Adult Patients on Antiretroviral Therapy in Armed Force Comprehensive and Specialized Hospital, Addis Ababa, Ethiopia
por: Kemal A, et al.
Publicado: (2020) -
Ergotismo secundario a la asociación ergotamina-ritonavir: A propósito de 3 casos
por: Acle,Santiago, et al.
Publicado: (2011) -
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley RD, et al.
Publicado: (2016)